Panacea Index Logo

Command Palette

Search for a command to run...

Erythropoietin and intravenous iron in PBM.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
February 1, 2014
Fiona E Ralley
Journal ArticleReviewHuman Study
Study Details

Study Goal

The researchers aimed to evaluate the role of iron supplementation, either oral or intravenous, with or without erythropoietin, in optimizing preoperative hemoglobin for patients with anemia.

Results Summary

The study suggests that iron supplementation, particularly intravenous iron, along with erythrocyte stimulating agents (ESAs), can effectively optimize preoperative hemoglobin and red blood cell mass in anemic patients. Different formulations of intravenous iron and the indications/contraindications for ESAs are discussed.

Population

Preoperative patients with anemia.

Effective Dosage

Not specified

Duration

Not specified

Interactions

None mentioned

Extracted Claims (6)
InterventionDirectionEndpointPopulationDosageImpactClaim #
iron supplementation, either oral or intravenous
increase
preoperative hemoglobin
patient with anemia
-
optimization
#1
iron supplementation, either oral or intravenous
increase
hemopoiesis
patient with anemia
-
maximizing
#2
iron supplementation, either oral or intravenous
increase
RBC mass
patient with anemia
-
maximizing
#3
erythrocyte stimulating agents (ESAs) such as erythropoietin
increase
preoperative hemoglobin
patient with anemia
-
optimization
#4
erythrocyte stimulating agents (ESAs) such as erythropoietin
increase
hemopoiesis
patient with anemia
-
maximizing
#5
erythrocyte stimulating agents (ESAs) such as erythropoietin
increase
RBC mass
patient with anemia
-
maximizing
#6
Abstract

The concept of patient blood management is such that if a patient with anemia can be identified in the pre-operative period, therapeutic modalities can be targeted to that patient who might benefit from such treatment. Management strategies include the optimization of preoperative hemoglobin by maximizing hemopoiesis and RBC mass. This can best be achieved with the use of iron supplementation, either oral or intravenous, with or without the use of erythrocyte stimulating agents (ESAs) such as erythropoietin. The use of i.v. iron and ESAs is reviewed. Different i.v. iron formulations available are discussed along with current indications and contraindications for the use of ESAs.

Medical Subject Headings (MeSH)
Administration, IntravenousAnemiaBlood PreservationBlood TransfusionDietary SupplementsErythrocytesErythropoietinHematinicsHumansIronPreoperative Period
Study Links
Quality Scores
SafetyNot Assessed
Efficacy75/10
Quality65/10
Citation Metrics
Total Citations7
Citations/Year0.6
Relative Citation Ratio0.35
NIH Percentile18.7%
Research Impact Scores
APT Score0.25
Weight Score0.67
Normalized Score0.63
Related Supplements
Erythropoietin and intravenous iron in PBM. | Panacea Index